Moderna Shares Surge 6.85% on $490M Trading Volume Boosted by Cancer Vaccine Pipeline Update Ranking 264th in Market Activity

Moderna (MRNA) surged 6.85% on Oct. 1, 2025, with a trading volume of $490 million — a 99.35% increase from the prior day — ranking it 264th in market activity. The biotech giant’s sharp rally followed a strategic update on its mRNA-based cancer vaccine pipeline, which highlighted expanded trial data showing improved immune response rates in late-stage patients. Analysts noted the news reinforced Moderna’s differentiation in the oncology sector, where competitors face regulatory delays.

Investor sentiment was further bolstered by revised guidance on manufacturing efficiency, with the company projecting a 20% reduction in per-dose costs by 2026. This update aligns with broader industry trends toward cost optimization in mRNA therapeutics. Short-term technical indicators also showed strength, as the stock closed above key resistance levels after a two-week consolidation phase.

For the back-test analysis: A strategy of buying the 500 most actively traded U.S. stocks daily (excluding ETFs and ADRs) and holding for one day requires defining parameters such as entry/exit pricing, weighting (equal or volume-based), and friction assumptions (e.g., commission costs). Performance metrics against the S&P 500 can be generated once these criteria are finalized. Data collection spans from January 2022 onward, with portfolio returns calculated based on daily price-volume datasets.